Great Lakes Advisors LLC Makes New Investment in Gilead Sciences, Inc. $GILD

Posted by Brian Himes on Aug 20th, 2026

Gilead Sciences logo Great Lakes Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 62,450 shares of the biopharmaceutical company’s stock, valued at approximately $7,890,000.

Other hedge funds have also modified their holdings of the company. Paulson Wealth Management Inc. increased its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after buying an additional 71 shares during the period. Davidson Trust Co. boosted its holdings in Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the period. Alpha Cubed Investments LLC increased its stake in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares in the last quarter. Finally, Financial Connections Group Inc. raised its holdings in Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Barclays decreased their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $158.04.

Get Our Latest Report on Gilead Sciences

Gilead Sciences Trading Up 2.9%

GILD opened at $147.60 on Thursday. The firm has a market cap of $183.02 billion, a P/E ratio of -55.28 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a 50-day moving average of $131.21 and a 200 day moving average of $136.51. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 EPS. Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 82,000 shares of company stock worth $10,837,860. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.